Headshots of 2021 Pilot Award Recipients

MEET OUR YOUNG INVESTIGATOR PILOT AWARD RECIPIENTS!

The ACSR is committed to supporting the next generation of HIV researchers by offering a grant award program for early-stage investigators interested in conducting HIV-related research, especially for malignancies. The goal is to encourage novel and rigorous scientific research projects that utilize biospecimens and data in the ACSR inventory via a small grant funding mechanism and contribute toward greater understanding of HIV disease, biology, improved treatment, and discovery of a cure.  See below to learn more about our YOUNG INVESTIGATOR PILOT AWARD (YIPA) opportunities as well as our past and current awardees. Click here to register for email updates about this and other HIV funding opportunities.

  • ACSR YOUNG INVESTIGATOR PILOT AWARD: CURRENT LOI CYCLE IS CLOSED!  Please contact us for more information on upcoming cycles.

Other Funding Opportunities

National Institutes of Health (NIH) Funding Opportunity Announcements

  • Notice of Funding Opportunity (NOFO), Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional): RFA-CA-24-006 National Cancer Institute (NCI) intends to support basic and translational #research that will guide the development of a prophylactic or therapeutic Kaposi Sarcoma herpesvirus (KSHV) vaccine to prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such as multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and KSHV inflammatory cytokine syndrome (KICS), or ameliorate the severity of disease. A therapeutic KSHV vaccine could be helpful in preventing or treating KSHV disease in people already infected with KSHV. Earliest submission date: November 21, 2023. Expiration date: December 05, 2024
  • Notice of Special Interest (NOSI): Pragmatic Trials in Low Resource Settings: NOT-CA-23-078 National Cancer Institute (NCI) encourages applications for pragmatic clinical trials to generate evidence that directly informs decision-making among patients, providers, health systems, communities, and policy makers in LMICs with the goal of improving efficiency, quality, and access for cancer care in resource-constrained settings.  Expiration Date: November 18, 2025
  • Notice of Special Interest (NOSI): Research on HIV-associated Malignancies NOT-CA-23-070. National Cancer Institute (NCI) intends to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), which are now a leading cause of death in people with HIV (PWH). This NOSI calls for proposals that seek to identify specific contributions of HIV infection and its potential interaction with other oncogenic pathogens on the development and pathogenesis of these cancers, including studies that provide new information on the clinical outcomes of such cancers in the HIV-infected population. Expiration date: September 08, 2026